Cargando…
Molecular benchmarks of a SARS-CoV-2 epidemic
A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206085/ https://www.ncbi.nlm.nih.gov/pubmed/34131116 http://dx.doi.org/10.1038/s41467-021-23883-6 |
_version_ | 1783708571923382272 |
---|---|
author | Jonsson, Hakon Magnusson, Olafur T. Melsted, Pall Berglund, Jonas Agustsdottir, Arna B. Eiríksdottir, Berglind Fridriksdottir, Run Garðarsdottir, Elisabet Eir Georgsson, Gudmundur Gretarsdottir, Olafia S. Guðmundsson, Kjartan R. Gunnarsdottir, Thora Rosa Eggertsson, Hannes Gylfason, Arnaldur Holm, Hilma Jensson, Brynjar O. Jonasdottir, Aslaug Jonsson, Frosti Josefsdottir, Kamilla S. Thordardottir, Marianna Kristinsson, Karl G. Kristjánsson, Þórður Magnusdottir, Droplaug N. Roux, Louise le Saemundsdottir, Jona Sigurdsson, Asgeir Sigmundsdottir, Gudrun Sveinbjornsson, Gardar Rognvaldsson, Solvi Eiriksson, Ogmundur Magnusson, Magnus Karl Sveinsdottir, Kristin Eva Sveinsdottir, Maney Thorarensen, Emil Aron Thorbjornsson, Bjarni Löve, Arthur Norddahl, Gudmundur L. Jonsdottir, Ingileif Sulem, Patrick Masson, Gisli Moller, Alma Gudnason, Thorolfur Kristjansson, Mar Helgason, Agnar Gudbjartsson, Daniel F. Thorsteinsdottir, Unnur Stefansson, Kari |
author_facet | Jonsson, Hakon Magnusson, Olafur T. Melsted, Pall Berglund, Jonas Agustsdottir, Arna B. Eiríksdottir, Berglind Fridriksdottir, Run Garðarsdottir, Elisabet Eir Georgsson, Gudmundur Gretarsdottir, Olafia S. Guðmundsson, Kjartan R. Gunnarsdottir, Thora Rosa Eggertsson, Hannes Gylfason, Arnaldur Holm, Hilma Jensson, Brynjar O. Jonasdottir, Aslaug Jonsson, Frosti Josefsdottir, Kamilla S. Thordardottir, Marianna Kristinsson, Karl G. Kristjánsson, Þórður Magnusdottir, Droplaug N. Roux, Louise le Saemundsdottir, Jona Sigurdsson, Asgeir Sigmundsdottir, Gudrun Sveinbjornsson, Gardar Rognvaldsson, Solvi Eiriksson, Ogmundur Magnusson, Magnus Karl Sveinsdottir, Kristin Eva Sveinsdottir, Maney Thorarensen, Emil Aron Thorbjornsson, Bjarni Löve, Arthur Norddahl, Gudmundur L. Jonsdottir, Ingileif Sulem, Patrick Masson, Gisli Moller, Alma Gudnason, Thorolfur Kristjansson, Mar Helgason, Agnar Gudbjartsson, Daniel F. Thorsteinsdottir, Unnur Stefansson, Kari |
author_sort | Jonsson, Hakon |
collection | PubMed |
description | A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures. |
format | Online Article Text |
id | pubmed-8206085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82060852021-07-01 Molecular benchmarks of a SARS-CoV-2 epidemic Jonsson, Hakon Magnusson, Olafur T. Melsted, Pall Berglund, Jonas Agustsdottir, Arna B. Eiríksdottir, Berglind Fridriksdottir, Run Garðarsdottir, Elisabet Eir Georgsson, Gudmundur Gretarsdottir, Olafia S. Guðmundsson, Kjartan R. Gunnarsdottir, Thora Rosa Eggertsson, Hannes Gylfason, Arnaldur Holm, Hilma Jensson, Brynjar O. Jonasdottir, Aslaug Jonsson, Frosti Josefsdottir, Kamilla S. Thordardottir, Marianna Kristinsson, Karl G. Kristjánsson, Þórður Magnusdottir, Droplaug N. Roux, Louise le Saemundsdottir, Jona Sigurdsson, Asgeir Sigmundsdottir, Gudrun Sveinbjornsson, Gardar Rognvaldsson, Solvi Eiriksson, Ogmundur Magnusson, Magnus Karl Sveinsdottir, Kristin Eva Sveinsdottir, Maney Thorarensen, Emil Aron Thorbjornsson, Bjarni Löve, Arthur Norddahl, Gudmundur L. Jonsdottir, Ingileif Sulem, Patrick Masson, Gisli Moller, Alma Gudnason, Thorolfur Kristjansson, Mar Helgason, Agnar Gudbjartsson, Daniel F. Thorsteinsdottir, Unnur Stefansson, Kari Nat Commun Article A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures. Nature Publishing Group UK 2021-06-15 /pmc/articles/PMC8206085/ /pubmed/34131116 http://dx.doi.org/10.1038/s41467-021-23883-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jonsson, Hakon Magnusson, Olafur T. Melsted, Pall Berglund, Jonas Agustsdottir, Arna B. Eiríksdottir, Berglind Fridriksdottir, Run Garðarsdottir, Elisabet Eir Georgsson, Gudmundur Gretarsdottir, Olafia S. Guðmundsson, Kjartan R. Gunnarsdottir, Thora Rosa Eggertsson, Hannes Gylfason, Arnaldur Holm, Hilma Jensson, Brynjar O. Jonasdottir, Aslaug Jonsson, Frosti Josefsdottir, Kamilla S. Thordardottir, Marianna Kristinsson, Karl G. Kristjánsson, Þórður Magnusdottir, Droplaug N. Roux, Louise le Saemundsdottir, Jona Sigurdsson, Asgeir Sigmundsdottir, Gudrun Sveinbjornsson, Gardar Rognvaldsson, Solvi Eiriksson, Ogmundur Magnusson, Magnus Karl Sveinsdottir, Kristin Eva Sveinsdottir, Maney Thorarensen, Emil Aron Thorbjornsson, Bjarni Löve, Arthur Norddahl, Gudmundur L. Jonsdottir, Ingileif Sulem, Patrick Masson, Gisli Moller, Alma Gudnason, Thorolfur Kristjansson, Mar Helgason, Agnar Gudbjartsson, Daniel F. Thorsteinsdottir, Unnur Stefansson, Kari Molecular benchmarks of a SARS-CoV-2 epidemic |
title | Molecular benchmarks of a SARS-CoV-2 epidemic |
title_full | Molecular benchmarks of a SARS-CoV-2 epidemic |
title_fullStr | Molecular benchmarks of a SARS-CoV-2 epidemic |
title_full_unstemmed | Molecular benchmarks of a SARS-CoV-2 epidemic |
title_short | Molecular benchmarks of a SARS-CoV-2 epidemic |
title_sort | molecular benchmarks of a sars-cov-2 epidemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206085/ https://www.ncbi.nlm.nih.gov/pubmed/34131116 http://dx.doi.org/10.1038/s41467-021-23883-6 |
work_keys_str_mv | AT jonssonhakon molecularbenchmarksofasarscov2epidemic AT magnussonolafurt molecularbenchmarksofasarscov2epidemic AT melstedpall molecularbenchmarksofasarscov2epidemic AT berglundjonas molecularbenchmarksofasarscov2epidemic AT agustsdottirarnab molecularbenchmarksofasarscov2epidemic AT eiriksdottirberglind molecularbenchmarksofasarscov2epidemic AT fridriksdottirrun molecularbenchmarksofasarscov2epidemic AT garðarsdottirelisabeteir molecularbenchmarksofasarscov2epidemic AT georgssongudmundur molecularbenchmarksofasarscov2epidemic AT gretarsdottirolafias molecularbenchmarksofasarscov2epidemic AT guðmundssonkjartanr molecularbenchmarksofasarscov2epidemic AT gunnarsdottirthorarosa molecularbenchmarksofasarscov2epidemic AT eggertssonhannes molecularbenchmarksofasarscov2epidemic AT gylfasonarnaldur molecularbenchmarksofasarscov2epidemic AT holmhilma molecularbenchmarksofasarscov2epidemic AT jenssonbrynjaro molecularbenchmarksofasarscov2epidemic AT jonasdottiraslaug molecularbenchmarksofasarscov2epidemic AT jonssonfrosti molecularbenchmarksofasarscov2epidemic AT josefsdottirkamillas molecularbenchmarksofasarscov2epidemic AT thordardottirmarianna molecularbenchmarksofasarscov2epidemic AT kristinssonkarlg molecularbenchmarksofasarscov2epidemic AT kristjanssonþorður molecularbenchmarksofasarscov2epidemic AT magnusdottirdroplaugn molecularbenchmarksofasarscov2epidemic AT rouxlouisele molecularbenchmarksofasarscov2epidemic AT saemundsdottirjona molecularbenchmarksofasarscov2epidemic AT sigurdssonasgeir molecularbenchmarksofasarscov2epidemic AT sigmundsdottirgudrun molecularbenchmarksofasarscov2epidemic AT sveinbjornssongardar molecularbenchmarksofasarscov2epidemic AT rognvaldssonsolvi molecularbenchmarksofasarscov2epidemic AT eirikssonogmundur molecularbenchmarksofasarscov2epidemic AT magnussonmagnuskarl molecularbenchmarksofasarscov2epidemic AT sveinsdottirkristineva molecularbenchmarksofasarscov2epidemic AT sveinsdottirmaney molecularbenchmarksofasarscov2epidemic AT thorarensenemilaron molecularbenchmarksofasarscov2epidemic AT thorbjornssonbjarni molecularbenchmarksofasarscov2epidemic AT lovearthur molecularbenchmarksofasarscov2epidemic AT norddahlgudmundurl molecularbenchmarksofasarscov2epidemic AT jonsdottiringileif molecularbenchmarksofasarscov2epidemic AT sulempatrick molecularbenchmarksofasarscov2epidemic AT massongisli molecularbenchmarksofasarscov2epidemic AT molleralma molecularbenchmarksofasarscov2epidemic AT gudnasonthorolfur molecularbenchmarksofasarscov2epidemic AT kristjanssonmar molecularbenchmarksofasarscov2epidemic AT helgasonagnar molecularbenchmarksofasarscov2epidemic AT gudbjartssondanielf molecularbenchmarksofasarscov2epidemic AT thorsteinsdottirunnur molecularbenchmarksofasarscov2epidemic AT stefanssonkari molecularbenchmarksofasarscov2epidemic |